5B474B14-FB1C-4B54-A9E8-3D652ADE6BA4
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 18.00262812089356
- age_years
- 74
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.615
- G2M_CHECKPOINT+0.541
- MYC_TARGETS_V2+0.535
- MYC_TARGETS_V1+0.518
- DNA_REPAIR+0.506
- CHOLESTEROL_HOMEOSTASIS+0.479
- MTORC1_SIGNALING+0.478
- GLYCOLYSIS+0.432
- NOTCH_SIGNALING+0.356
- OXIDATIVE_PHOSPHORYLATION+0.350
Top 10 suppressed
- KRAS_SIGNALING_DN-0.365
- PANCREAS_BETA_CELLS-0.182
- MYOGENESIS-0.170
- SPERMATOGENESIS-0.150
- APICAL_SURFACE-0.120
- INFLAMMATORY_RESPONSE-0.107
- ALLOGRAFT_REJECTION-0.104
- ESTROGEN_RESPONSE_EARLY-0.044
- HEDGEHOG_SIGNALING-0.013
- KRAS_SIGNALING_UP+0.017
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 23F34B20-F029-44F5-B3B5-06A74FC0FC9D | — | — | 0.948 |
| 2 | 2566FDAC-EF10-4996-8890-FA0BEC771676 | — | — | 0.945 |
| 3 | 52F6F0A9-8D2D-49BC-9B49-E20E5E53561C | — | — | 0.932 |
| 4 | 4FE5EDE2-7790-4A75-9BB6-93260A8154A0 | — | — | 0.929 |
| 5 | 94640BD8-E1D9-482D-A597-4790F6EEA6B7 | — | — | 0.925 |
| 6 | ECCC2F18-409F-41BA-B49F-95B23893B80B | — | — | 0.922 |
| 7 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.918 |
| 8 | C5C8713B-05C1-4C5C-8685-2A546B99BA50 | — | — | 0.917 |
| 9 | 569BCFB6-7B4D-459A-962A-4C148889CE2C | — | — | 0.916 |
| 10 | 33800B09-6DCC-4BE8-891C-5F34ADAC65B3 | — | — | 0.909 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.615 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.541 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.535 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.518 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.506 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.479 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.478 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.432 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.356 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.349 | Idelalisib | — uncovered |
| HYPOXIA | 0.344 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.343 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.339 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.328 | Inavolisib | — uncovered |
| PEROXISOME | 0.312 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.289 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.285 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.284 | Idelalisib | — uncovered |